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Background: Left atrial appendage occlusion with the Amplatzer Cardiac Plug
Device (ACP) (St Jude Medical, Minneapolis, MN) for non valvular atrial ﬁbrilla-
tion(NVAF) and contraindications to oral anticoagulant therapy (OAC) is showing to
be feasible and safe but there is lack of data as for the long term follow up.
Methods: We report the follow up of 134 patients treated with ACP device from 1/
2009 to 12/2012 in two Italian centers. Most patients received short-term (1-3 months)
dual antiplatelet therapy following the procedure and single antiplatelet therapy
thereafter. Follow up was carried out by clinical visits or phone contact at 1, 6 and 12
months and yearly thereafter. A total of 93(72.6%) patients received imaging follow-
up 6 months after the procedure either by transesophageal echography(TEE) or by
cardiac CT scan. The presence of device thrombosis and residual leak were evaluated.
Results: Mean age and median CHADS2 were 768 years and 3 respectively. The
procedure was successful in 96% of the patients. Main complications were pericardial
effusion (4.4%) with 2 cases of cardiac tamponade (1.4%), 1 hemorragic stroke and 1
TIA. Median follow up was 22 months (range 1.4 – 53.6). The longest follow up was 4
years for 4 patients. 26 patients had a follow up of 3 years. 110 patients had a follow up of
>¼12months. The rates of death, stroke, TIA and systemic embolism at follow-up, were
5.5%, 1.5%, 2.3% and 0%, respectively. The presence of peri device leak was observed
in 5.4% of patients at 6-months imaging follow-up. No massive leak was observed.
There was one case of device thrombosis that resolved after 1 month of anticoagulation.
The expected stroke rate was 8.6% versus an observed stroke rate of 1.5% (p<0.01).
Conclusions: Our follow up of patients treated with ACP device for NVAF and
contraindications to OAC demonstrates the efﬁcacy of the procedure in preventing
stroke over a long time period (110 pts followed for >1 year), with a signiﬁcant
reduction of the risk of stroke as compared with the expected incidence. The imaging
follow-up showed low incidence of signiﬁcant residual leaks. We also conﬁrm the
feasibility and safety of the LAAO procedure.
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Background: Percutaneous left ventricular transapical access (TA) can be utilized for
a multitude of diagnostic and interventional procedures in structural heart disease
(SHD). With advancements in imaging and device technology, applicability of this
approach is expanding. We present our growing experience in utilizing TA for
structural heart interventions.
Methods: We evaluated patients at our center, from April 2008 to June 2013, who
presented for SHD intervention. Ninety four TA were performed in 80 consecutive
patients (54 males, 7130 years) with 4 patients having double TA during the same
intervention and 10 patients having repeat TA during subsequent SHD interventions
(double TA n¼13). Since August 2010, computed tomographic angiography (CTA)/
ﬂuoroscopy fusion imaging (HeartNavigator, Philips, Netherlands) has been used to
guide TA puncture.
Results: All TA were successfully performed for the following interventions: 74
mitral paravalvular leak (PVL) closure, 6 aortic PVL closure, 14 left ventricular
pseudoaneurysm (LVPA) closure, 2 ventricular septal defect closure, 8 mitral trans-
catheter valve-in-valve implantations, and 10 combined procedures. Average initial/
ﬁnal sheath sizes were 6F and 7F (range 5F-12F). TA was closed using an Amplatzer
Ductal Occluder n¼86, Amplatzer Vascular Plug II n¼3, Muscular VSD Occluder
n¼3, and coils n¼2. Complications occurred in 13 cases (14%): hemothorax n¼5,
pericardial effusion/tamponade n¼1; persistent access site bleeding requiring surgical
closure n¼2, non-fatal device migration n¼3 (2 ventricular, 1 epicardial requiring
surgical closure), and death n¼2. One death occurred in a patient with suprasystemic
pulmonary hypertension developing pulseless electrical activity and one death
occurred after PVL closure in the setting of untreated critical aortic stenosis and
epicardial device migration. There was no signiﬁcant difference in complications
associated with use of fusion imaging (with 10% vs without 17.6%, p¼0.29).
Conclusions: TA is useful in multiple SHD interventions. Despite fusion imaging,
complications still occur. More reliable TA closure devices may further improve the
safety and generalizabilty of this approach for more complex SHD interventions.B32 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT ATCT-99
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Background: Patients with a patent foramen ovale (PFO) and a history of paradoxical
embolism are at risk to suffer from recurrent events even if the PFO was closed
percutaneously. This study investigated the long-term results of a high-volume center.
Methods: PFOs were closed in patients with a history of at least one assumed para-
doxical embolism (TIA, stroke or peripheral embolism) or a diving accident. The type of
closure device was chosen due to availability and operator's decision. All patients were
prescribed a dual antiplatelet therapy (aspirin and clopidogrel) for the ﬁrst 6months after
the procedure. Echocardiographic studies were performed at 4 weeks and 6 months after
the index procedure. Patients were evaluated for residual shunts and the incidence of
potential adverse events. All patients were followed annually through ofﬁce visits,
questionnaires and phone calls, or by contacting the referring physicians.
Results: Between August 1998 and December 2012 percutaneous closure of patent
foramen ovale was performed in 2831 patients. The mean age of patients was 50  13
years. 55% were male (n¼1551). Indication for PFO-closure was a history of migraine
(n¼481), peripheral embolism (n¼55), diving accident (n¼36) or cryptogenic cerebral
ischemia (TIA in n¼1334 or stroke in n¼1666). 563 patients (19.9%) suffered from
recurrent neurological events before percutaneous PFO-closure. We used 23 different
types of closure devices. The most commonly used occluders were the Amplatzer
(n¼914), the Helex (n¼470), the Premere (n¼409) and the CardioSEAL-STARﬂex
device (n¼303). Within a total of 8,873 patient years of follow-up (mean follow-up
duration: 38 months), there were 89 recurrent embolic events. This compares to an
annual event rate of 1.0%. 29 patients suffered from recurrent TIA, and in 54 patients
an ischemic strokes occurred. In 6 patients peripheral embolic events occurred. In 122
patients (4.3%) a second device implantation was performed to close a residual shunt.
Conclusions: The results of this study represent the clinical experience of a European
high-volume center in PFO-closure and show a favorable and much lower annual
recurrent event rate compared to previously published randomized trials.
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Background: We assessed the predictors of length of hospital stay (LOS) and cost of
care related to percutaneous closure of ASD and PFO closure.
Methods: We examined the Healthcare Cost and Utilization Project's Nationwide
Inpatient Sample (NIS) database from 2001 to 2010 using ICD 9-CM code for
percutaneous ASD/PFO closure (35.52). Only adult (age > 18 year) patients with
ASD/PFO (ICD 9-CM - 745.5) were included in study. We could not differentiate
between ASD and PFO closure due to the same ICD9 code for both procedures. NIS is
represents 20% of all US hospitals. Cost to charge ratio ﬁles were merged with NIS to
calculate cost of care. Cost was adjusted for inﬂation in reference to 2010. Comorbid
conditions were deﬁned by Charlson's Comorbidity Index (CCI). Hierarchical
multilevel regression models were generated to determine independent predictors of
LOS and cost of care.
Results: Total of 7,107 (weighted n¼34,990) percutaneous ASD/PFO closure
procedures were analyzed. Average LOS and cost of care for percutaneous ASD/PFO
closure were 2.630.06 days and $16,635225, respectively. LOS was increased
(days, 95% CI, P-value) with presence of any complication (+2.47 days, 2.14-2.80,
P 2 (+1.84 days, 1.48-2.20, P<0.001). Decrease in LOS was associated with use
of higher operator volume tertile(-2.58 days, -3.04 - -2.12, P2) (1.17, 1.12-1.22,
P<0.001). Decrease in cost was associated with higher annual operator volume tertile
(0.84, 0.08 - 0.88, P<0.001).bstracts/ORAL/Percutaneous Treatment of Non-valvular Structural Heart Disease
